-+ 0.00%
-+ 0.00%
-+ 0.00%

Angelini Ventures joins Epicrispr $90 million Series C round

PUBT·08/11/2026 14:50:38
Listen to the news
Angelini Ventures joins Epicrispr $90 million Series C round
  • Angelini Ventures joined Epicrispr Biotechnologies’ oversubscribed Series C financing round sized at $90 million.
  • Epicrispr is a clinical-stage biotech developing programmable epigenetic medicines to modulate gene expression without changing DNA sequence.
  • Proceeds will advance EPI-321, an epigenetic therapy candidate designed to durably silence aberrant DUX4 activity in FSHD, toward pivotal studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.